Stock Price Movement and Market Context
On 1 Feb 2026, Genpharmasec Ltd’s shares touched Rs.0.98, the lowest level recorded in the past 52 weeks and also an all-time low. This represents a sharp fall from its 52-week high of Rs.2.63, indicating a decline of approximately 62.7% over the period. The stock underperformed its sector by 1.93% on the day it hit this low, with a day change of -0.85%. Furthermore, Genpharmasec is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent downtrend.
In contrast, the broader market has shown resilience. The Sensex opened 119.19 points higher and was trading at 82,485.33, up 0.26% on the same day. The Sensex remains just 4.45% below its 52-week high of 86,159.02. Mega-cap stocks are leading the market gains, while the Sensex’s 50-day moving average remains above its 200-day moving average, suggesting a generally positive market environment that Genpharmasec has not mirrored.
Financial Performance and Fundamental Assessment
Genpharmasec’s financial metrics reveal several areas of concern that have contributed to the stock’s decline. The company has reported operating losses, which have weighed on its long-term fundamental strength. Over the last five years, operating profit has grown at a modest annual rate of 4.13%, indicating limited growth momentum. Additionally, the company’s ability to service its debt is weak, with an average EBIT to interest ratio of -0.64, reflecting challenges in covering interest expenses from earnings before interest and tax.
Despite the negative stock performance, the company’s profits have risen by 105% over the past year. However, this improvement has not translated into positive returns for shareholders, as the stock has generated a negative return of -49.57% during the same period. The PEG ratio stands at 1.1, suggesting that the stock is trading at a valuation that does not fully reflect its earnings growth potential.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Comparative Performance and Risk Profile
Genpharmasec’s stock has underperformed not only its sector but also the broader BSE500 index over multiple time frames. The stock’s negative return of -49.57% over the last year contrasts sharply with the Sensex’s positive 7.46% return. This underperformance extends to the last three years and the recent three-month period, indicating a sustained period of below-par returns.
The company’s Mojo Score currently stands at 17.0, with a Mojo Grade of Strong Sell, upgraded from a previous Sell rating on 21 Jan 2025. This grading reflects the stock’s weak fundamentals and elevated risk profile. The market capitalisation grade is 4, indicating a relatively small market cap compared to peers. The stock’s valuation appears risky relative to its historical averages, further underscoring the cautious stance reflected in its grading.
Recent Operational Highlights
Despite the challenges, Genpharmasec reported some positive operational metrics in recent quarters. The company’s operating cash flow for the year reached a high of Rs.2.99 crores, while net sales for the quarter peaked at Rs.32.64 crores. These figures suggest pockets of strength in cash generation and revenue, although they have not yet translated into a reversal of the stock’s downward trend.
The majority of the company’s shares are held by non-institutional investors, which may influence trading dynamics and liquidity considerations.
Holding Genpharmasec Ltd from Trading & Distributors? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
To summarise, Genpharmasec Ltd’s stock has reached a significant low point at Rs.0.98, reflecting a nearly 50% decline over the past year and a substantial underperformance relative to the Sensex and its sector. The company’s financial indicators highlight ongoing challenges, including operating losses, limited long-term growth, and a weak debt servicing capacity. While recent cash flow and sales figures show some improvement, these have not yet influenced the stock’s overall trajectory.
The stock’s current Mojo Grade of Strong Sell and a low Mojo Score of 17.0 further illustrate the cautious outlook based on fundamental and valuation factors. Trading below all major moving averages, the stock remains in a downtrend, contrasting with the broader market’s positive momentum.
Investors and market participants will continue to monitor Genpharmasec’s financial performance and market behaviour as it navigates these challenges within the Trading & Distributors sector.
Unlock special upgrade rates for a limited period. Start Saving Now →
